Theseus Pharmaceuticals Inc THRX

NAS: THRX | ISIN: US88369M1018   13/02/2024
4,060 USD (0,00%)
(0,00%)   13/02/2024

14 februari 2024 · Theseus Pharmaceuticals Announces Closing of Tender Offer · Persbericht

6 februari 2024 · SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AMAM, TGAN, CSTR, THRX · Persbericht

22 december 2023 · Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right · Persbericht

7 november 2023 · Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference · Persbericht

10 augustus 2023 · Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results · Persbericht

13 juli 2023 · Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST · Persbericht

31 mei 2023 · Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference · Persbericht

25 mei 2023 · Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST · Persbericht

11 mei 2023 · Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results · Persbericht

26 april 2023 · Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting · Persbericht

11 april 2023 · Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences · Persbericht

28 maart 2023 · Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium · Persbericht

9 maart 2023 · Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results · Persbericht

7 februari 2023 · Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference · Persbericht

5 januari 2023 · Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program · Persbericht

3 november 2022 · Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results · Persbericht

3 november 2022 · Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results · Persbericht

3 november 2022 · Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results · Persbericht

3 november 2022 · Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results · Persbericht

26 oktober 2022 · Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium · Persbericht

Mijn selecties